



ONCOCLÍNICAS DO BRASIL SERVIÇOS MÉDICOS S.A.

CNPJ/ME nº 12.104.241/0004-02

NIRE 35.300.493.699

Public Traded Company

B3: ONCO3

NOTICE TO THE MARKET

Oncoclínicas do Brasil Serviços Médicos S.A. (B3: ONCO3) (“Company”), informs its shareholders and the market about the completion of its 100% acquisition of the share capital of Microimagem Laboratório de Anatomia Patológica e Citopatologia LTDA. (“Microimagem”) through its subsidiary Idengene Medicina Diagnóstica S.A. (the “Transaction”).

Founded in 1994 by a group of experienced pathologists from the National Cancer Institute (INCA), Microimagem is a renowned laboratory specializing in surgical pathology, cytopathology and immunohistochemistry in the city of Rio de Janeiro.

The Transaction complements the oncological line of care offered by the Company in that city, ranging from diagnostics all the way to the outcome, and bringing more speed across all stages of treatment. Microimagem will become part of OCPM, Oncoclínicas’ precision medicine division, and will operate in an integrated fashion with our laboratory in São Paulo, through digital pathology, artificial intelligence and biomarker analysis for maximum accuracy in diagnostics and monitoring.

The Transaction value is R\$ 8 million, R\$ 4 million of which are being disbursed on this date and R\$ 4 million in 12 months.

Lastly, the Company informs that the completion of the Transaction is not subject to the provisions of article 256 of the Brazilian Corporate Law and, therefore, does not require approval by the Company's General Shareholders Meeting.

São Paulo, January 20, 2022.

Cristiano Camargo

Investor Relations Officer

Oncoclínicas do Brasil Serviços Médicos S.A.